Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: A single-center experience

BioScience Trends

Volumn 8, Issue 6, 2014, Pages 333-338

  Zhang, Wei ^a   Zhao, Gang ^a   Wei, Kai ^a   Zhang, Qingxiang ^a   Ma, Weiwei ^a   Song, Tianqiang ^a   Wu, Qiang ^a   Zhang, Ti ^a   Kong, Dalu ^a   Li, Qiang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Resection; Sorafenib

Indexed keywords

CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB;

ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; EVALUATION STUDY; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84920868302     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2014.01120     Document Type: Article

References (30)

1. Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: A population-based study. Int J Cancer. 2014. doi:10.1002/ijc.29227
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
4. Tang ZY. Hepatocellular carcinoma surgery--review of the past and prospects for the 21st century. J Surg Oncol. 2005; 91:95-96.
5. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience. Ann Surg. 2011; 253:745-758.
6. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD, Wu GB. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. Eur J Surg Oncol. 2012; 38:286-295.
7. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon a treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132:458-465.
8. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007; 245:831-842.
9. Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012; 255:8-17.
10. Clavien PA. Interferon: The magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007; 245:843-845.
11. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: A randomized controlled trial. Ann Surg. 2014. PMID:25072444.
12. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007; 47:684-690.
13. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66:11851-11858.
14. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10:25-34.
15. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
16. Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013; 27:555-561.
17. Saab S, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: Feasibility and efficacy. Exp Clin Transplant. 2010; 8:307-313.
18. Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant. 2014; 2014:913634.
19. Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer. 2009; 115:4646.
20. Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res. 2014; 44:523-531.
21. Folkman J. Tumor angiogenesis and tissue factor. Nat Med. 1996; 2:167-168.
22. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30:52-60.
23. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer. 2008; 8:592-603.
24. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Sub-analyses of a phase III trial. J Hepatol. 2012; 57:821-829.
25. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011; 140:1410-1426.
26. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011; 55:1041-1048.
27. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012; 143:1641-1649 e5.
28. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48:1312-1327.
29. Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med. 2014; 6:1561-1576.
30. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2014; 8:210-221.